AstraZeneca, Astellas & WHO lead the way with the ‘Most impactful emerging or global initiatives’ at eyeforpharma Barcelona Awards

AstraZeneca, Astellas & the World Health Organisation have been announced as the finalists for the ‘Most impactful emerging or global initiative’ award at the first eyeforpharma Barcelona Awards.

The names of the three shortlisted companies for this award, selected from over 100 nominations, were identified as the front-runners in innovation and value creation and were released as part of the much-anticipated list of finalists for the inaugural eyeforpharma Barcelona Awards.

While the projects from AstraZeneca & Astellas focus on outreach in the emerging markets of sub-Saharan Africa & Turkey respectively, the WHO Immunization App was shortlisted for its potential for global application as judges agreed it was “an innovative solution which could be expanded to other therapies”.

A comprehensive list of finalists and their project videos can be found online here: http://www.eyeforpharma.com/barcelona/awards-finalists.php

The winner will be announced at the very first eyeforpharma Barcelona Awards, sponsored by IMS Health, on Tuesday 18th March at the CCIB, Barcelona from 7.30pm, as part of the largest gathering of pharma executives, eyeforpharma Barcelona. The evening will be attended by the top 200 VIPs from the pharma industry.

For more information contact Awards Manager, Chloe Leighton on chloe@eyeforpharma.com or visit www.eyeforpharma.com/barcelona/awards

About Us

eyeforpharma is a hub for senior-level pharma executives, patient advocacy groups and other health experts to exchange ideas and stay up to date with shifting trends and practices within the pharmaceutical industry. We provide industry-focused commentary, events, reports, and other valuable expert-driven content. Our ultimate aim is to facilitate positive change through discussion and debate, enabling dialogue within the industry and driving the positive benefits that pharmaceuticals can offer. We actively respond to the aims and interests of our audience, so please get in touch if you think we can do even more.